Table 4.

Adverse event after bevacizumab/capecitabine treatment.

Adverse events	Any grade	Grade 3 or 4
Any event	157 (100%)	28 (17.8%)
Hand foot syndrome	92 (58.6%)	8 (5.1%)
Fatigue	24 (15.3%)	2 (1.3%)
Nausea	14 (8.9%)	4 (2.6%)
Vomiting	8 (5.1%)	3 (1.9%)
Mucositis	35 (22.3%)	2 (1.3%)
Diarrhoea	16 (10.2%)	1 (0.6%)
Neutropenia	39 (24.8%)	5 (3.2%)
Thrombocytopenia	54 (34.4%)	2 (1.3%)
Anaemia	96 (61.1%)	2 (1.3%)
LFT elevation	76 (48.4%)	2 (1.3%)
Bilirubin elevation	64 (40.8%)	5 (3.2%)
Proteinuria	10 (6.4%)	3 (1.9%)
Bleeding/haemorrhage	11 (7.0%)	2 (1.3%)
Gastrointestinal perforation	1 (0.6%)	1 (0.6%)
Thromboembolic event	0 (0.0%)	0 (0.0%)